Serotonin 5-HT2C receptor (agonist)

Class

diazepine-scaffold small molecule; a highly selective 5-HT2C receptor superagonist (no material activity at 5-HT2A or 5-HT2B) developed by Longboard Pharmaceuticals for developmental and epileptic encephalopathies

Pathway

selective 5-HT2C receptor activation is proposed to modulate GABAergic tone and suppress the central hyperexcitability underlying seizures

The 5-HT2C receptor is a G protein-coupled receptor for serotonin, a chemical messenger that influences mood, appetite, and the excitability of nerve cells in the brain. It belongs to a family of three related subtypes—5-HT2A, 5-HT2B, and 5-HT2C—that look similar structurally but produce different effects depending on where in the body they sit. A molecule designed to activate 5-HT2C selectively, while leaving 5-HT2A and 5-HT2B largely untouched, is built to isolate one specific benefit: calming excessive electrical activity in the brain, while avoiding the hallucinogenic effects linked to 5-HT2A and the heart valve damage historically linked to 5-HT2B. In epilepsy, especially severe childhood-onset developmental and epileptic encephalopathies, seizures result from an imbalance between excitatory and inhibitory signals in neural circuits. Selective 5-HT2C activation is thought to strengthen inhibitory GABAergic signaling, helping restrain the excessive excitatory activity that triggers seizures. This mechanism matters broadly wherever brain hyperexcitability drives disease, and is most relevant in seizure syndromes that resist standard anti-seizure medicines. Because the approach depends on precise receptor selectivity, distinguishing this agent from earlier, less selective serotonergic compounds is central to its therapeutic rationale.